Pfizer Inc and BioNTech could secure emergency US and European authorisation for their Covid-19 vaccine next month after final trial results showed it had a 95 per cent success rate and no serious side effects, the drugmakers said on Wednesday.
The vaccine’s efficacy was found to be consistent across different ages and ethnicities.
The US Food and Drug Administration could grant emergency-use by the middle of December, BioNTech Chief Executive Ugur Sahin told Reuters TV. Conditional approval in the European Union could be secured in the second half of December, he added.
